Argyle Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Argyle Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$549K	Hold	16,200	–	–	0.16%	108
2026 Q1	$488K	Hold	16,200	–	–	0.16%	109
2025 Q4	$506K	Hold	16,200	–	–	0.17%	108
2025 Q3	$327K	Hold	16,200	–	–	0.11%	118
2025 Q2	$272K	Hold	16,200	–	–	0.1%	124
2025 Q1	$249K	Hold	16,200	–	–	0.09%	123
2024 Q4	$357K	Hold	16,200	–	–	0.14%	112
2024 Q3	$292K	Hold	16,200	–	–	0.12%	111
2024 Q2	$263K	Sell	16,200 -1,400	-8%	-$21.6K	0.11%	115
2024 Q1	$248K	Sell	17,600 -1,450	-8%	-$18.3K	0.1%	111
2023 Q4	$199K	Sell	19,050 -11,800	-38%	-$110K	0.08%	112
2023 Q3	$315K	Hold	30,850	–	–	0.12%	110
2023 Q2	$232K	Sell	30,850 -1,500	-5%	-$12.2K	0.08%	115
2023 Q1	$286K	Hold	32,350	–	–	0.1%	117
2022 Q4	$295K	Hold	32,350	–	–	0.1%	114
2022 Q3	$261K	Sell	32,350 -100	-0.3%	-$884	0.1%	115
2022 Q2	$244K	Hold	32,450	–	–	0.09%	121
2022 Q1	$305K	Sell	32,450 -100	-0.3%	-$835	0.1%	119
2021 Q4	$261K	Sell	32,550 -9,300	-22%	-$83.9K	0.08%	117
2021 Q3	$408K	Sell	41,850 -1,700	-4%	-$15.9K	0.14%	110
2021 Q2	$431K	Hold	43,550	–	–	0.14%	111
2021 Q1	$503K	Hold	43,550	–	–	0.17%	102
2020 Q4	$420K	Sell	43,550 -600	-1%	-$5.75K	0.16%	105
2020 Q3	$398K	Sell	44,150 -800	-2%	-$8.46K	0.16%	104
2020 Q2	$554K	Hold	44,950	–	–	0.23%	91
2020 Q1	$404K	Hold	44,950	–	–	0.19%	99
2019 Q4	$441K	Sell	44,950 -7,250	-14%	-$64.7K	0.16%	106
2019 Q3	$359K	Sell	52,200 -5,600	-10%	-$42.9K	0.14%	108
2019 Q2	$533K	Hold	57,800	–	–	0.2%	102
2019 Q1	$906K	Hold	57,800	–	–	0.35%	80
2018 Q4	$891K	Buy	57,800 +1,000	+2%	+$20.5K	0.38%	77
2018 Q3	$1.22M	Sell	56,800 -2,000	-3%	-$46.4K	0.46%	70
2018 Q2	$1.43M	Sell	58,800 -1,000	-2%	-$20.4K	0.57%	63
2018 Q1	$1.02M	Sell	59,800 -950	-2%	-$18.5K	0.41%	74
2017 Q4	$1.15M	Buy	60,750 +3,598	+6%	+$54.1K	0.43%	73
2017 Q3	$1.01M	Buy	57,152 +300	+0.5%	+$6.75K	0.39%	73
2017 Q2	$1.89M	Buy	56,852 +4,600	+9%	+$142K	0.77%	54
2017 Q1	$1.68M	Buy	52,252 +1,800	+4%	+$61.4K	0.68%	57
2016 Q4	$1.83M	Buy	50,452 +12,900	+34%	+$515K	0.78%	55
2016 Q3	$1.73M	Buy	37,552 +50	+0.1%	+$2.61K	0.75%	55
2016 Q2	$1.88M	Buy	37,502 +3,630	+11%	+$193K	0.8%	54
2016 Q1	$1.81M	Sell	33,872 -100	-0.3%	-$5.87K	0.82%	53
2015 Q4	$2.23M	Hold	33,972	–	–	1.03%	43
2015 Q3	$1.92M	Sell	33,972 -750	-2%	-$48.6K	0.94%	48
2015 Q2	$2.05M	Sell	34,722 -930	-3%	-$57.4K	0.94%	46
2015 Q1	$2.22M	Hold	35,652	–	–	0.99%	44
2014 Q4	$2.05M	Hold	35,652	–	–	0.9%	50
2014 Q3	$1.92M	Hold	35,652	–	–	0.88%	50
2014 Q2	$1.87M	Hold	35,652	–	–	0.87%	50
2014 Q1	$1.88M	Sell	35,652 -800	-2%	-$37K	0.93%	45
2013 Q4	$1.46M	Sell	36,452 -2,900	-7%	-$114K	0.74%	50
2013 Q3	$1.49M	Buy	39,352 +5,400	+16%	+$211K	0.82%	50
2013 Q2	$1.33M	Buy	+33,952	New	+$1.32M	0.76%	51

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Argyle Capital Management's TEVA Position: Q2 2026 in Review

Argyle Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 16,200 shares worth $549K. The position accounts for 0.16% of the portfolio, ranked #108.

Argyle Capital Management first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.23M in Q4 2015. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Argyle Capital Management held 16,200 shares of Teva Pharmaceuticals worth $549K as of Q2 2026.
Argyle Capital Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up 0.16% of Argyle Capital Management's portfolio in Q2 2026, its #108 holding.
Argyle Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Argyle Capital Management's Teva Pharmaceuticals position peaked at $2.23M in Q4 2015.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Argyle Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.